A5042184078- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- Peptidase Inhibition and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Prostate Cancer Diagnosis and Treatment
- Protease and Inhibitor Mechanisms
- Mass Spectrometry Techniques and Applications
- Cancer, Hypoxia, and Metabolism
- Receptor Mechanisms and Signaling
- Click Chemistry and Applications
- RNA Interference and Gene Delivery
- Glioma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Fluorine in Organic Chemistry
- X-ray Diffraction in Crystallography
- Chemical Reactions and Isotopes
- Crystallization and Solubility Studies
- Nanoplatforms for cancer theranostics
- Neuroblastoma Research and Treatments
- Chemical Synthesis and Analysis
- Immunotherapy and Immune Responses
- Lanthanide and Transition Metal Complexes
- Cancer, Lipids, and Metabolism
- Neuroendocrine Tumor Research Advances
German Cancer Research Center
2015-2025
Deutschen Konsortium für Translationale Krebsforschung
2016-2025
Technische Universität Dresden
2020-2025
Helmholtz-Zentrum Dresden-Rossendorf
2020-2025
University Hospital Carl Gustav Carus
2022-2025
National Center for Tumor Diseases
2022-2025
German Marine Research Consortium
2017-2025
Nationales Centrum für Tumorerkrankungen Dresden
2025
German Cancer Society
2023-2024
Heidelberg University
2014-2023
Since the introduction of positron emission tomography (PET) imaging with 68Ga-PSMA-HBED-CC (=68Ga-DKFZ-PSMA-11), this method has been regarded as a significant step forward in diagnosis recurrent prostate cancer (PCa). However, published data exist for small patient cohorts only. The aim evaluation was to analyse diagnostic value 68Ga-PSMA-ligand PET/CT large cohort and influence several possibly interacting variables. We performed retrospective analysis 319 patients who underwent from 2011...
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand. Although case series still ongoing, here report advance about two patients highly challenging clinical situations who showed complete response to <sup>225</sup>Ac-PSMA-617 therapy. <b>Methods:</b><sup>68</sup>Ga-PSMA-11 PET/CT validated presence of PSMA-positive tumor phenotype. A 100-kBq activity per kilogram body...
Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long tumor retention, the DOTA-conjugated ligand PSMA-617 has low kidney uptake, making it choice therapeutic application. We retrospectively report our experience with <sup>177</sup>Lu-PSMA-617–targeted in a case series mCRPC patients resistant to other treatments. <b>Methods:</b> Patients PSMA-positive phenotypes...
Despite many advances in the past years, treatment of metastatic prostate cancer still remains challenging. In recent prostate-specific membrane antigen (PSMA) inhibitors were intensively studied to develop low-molecular-weight ligands for imaging lesions by PET or SPECT. However, endoradiotherapeutic use these compounds requires optimization with regard radionuclide-chelating agent and linker moiety between chelator pharmacophore, which influence overall pharmacokinetic properties resulting...
The prostate-specific membrane antigen (PSMA) targeted positron-emitting-tomography (PET) tracer 68Ga-PSMA-11 shows great promise in the detection of prostate cancer. However, 68Ga has several shortcomings as a radiolabel including short half-life and non-ideal energies, this motivated consideration 18F-labelled analogs. 18F-PSMA-1007 was selected among 18F-PSMA-ligand candidate compounds because it demonstrated high labelling yields, outstanding tumor uptake fast, non-urinary background...
Abstract Purpose Since the clinical introduction of 68 Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in diagnosis recurrent prostate cancer (PCa). The aim study was to analyse influence several variables with possible on PSMA ligand uptake large cohort. Methods We performed retrospective analysis 1007 consecutive patients who were scanned PET/CT (1 h after injection) from January 2014 2017 detect disease. Patients untreated...
PET imaging with the prostate-specific membrane antigen (PSMA)–targeted radioligand <sup>68</sup>Ga-PSMA-11 is regarded as a significant step forward in diagnosis of prostate cancer (PCa). More recently, PSMA ligand was developed that can be labeled <sup>68</sup>Ga, <sup>111</sup>In, <sup>177</sup>Lu, and <sup>90</sup>Y. This ligand, named PSMA-617, therefore enables both therapy PCa. The aims this evaluation were to clinically investigate distribution <sup>68</sup>Ga-PSMA-617 normal tissues...
The detection of prostate cancer lesions by PET imaging the prostate-specific membrane antigen (PSMA) has gained highest clinical impact during last years. 68Ga-labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-HBED-CC) represents a successful novel PSMA inhibitor radiotracer which recently demonstrated its suitability in individual first-in-man studies. radiometal chelator HBED-CC used this molecule rather rarely acyclic complexing agent with chemical characteristics favourably influencing...
Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting molecules are under development to detect and treat metastatic castration resistant (mCRPC). We investigated tissue kinetics of a small molecule inhibitor PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[124I]iodophenyl)ureido)pentyl)ureido)pentanedioicacid; MIP-1095) using PET/CT estimate radiation dosimetry for potential therapeutic use 131I-MIP-1095 men with mCRPC. also...
Prostate-specific membrane antigen (PSMA)–targeted PET imaging recently emerged as a new method for the staging and restaging of prostate cancer. Most published studies investigated diagnostic potential <sup>68</sup>Ga-labeled PSMA agents that are excreted renally. <sup>18</sup>F-PSMA-1007 is novel ligand has excellent preclinical characteristics only minimally by urinary tract, advantage pelvic imaging. The aim this study was to investigate efficacy biochemical recurrence (BCR) after...
Radiotherapy is the main therapeutic approach besides surgery of localized prostate cancer. It relies on risk stratification and exact staging. This report analyses potential [(68)Ga]Glu-urea-Lys(Ahx)-HBED-CC ((68)Ga-PSMA-11), a new positron emission tomography (PET) tracer targeting prostate-specific membrane antigen (PSMA) for cancer staging individualized radiotherapy planning.A cohort 57 patients with scanned (68)Ga-PSMA-11 PET/CT planning was retrospectively reviewed; 15 were at initial...
In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Some of them had a high clinical impact on treatment patients with prostate cancer. However, number <sup>18</sup>F-labeled tracers addressing PSMA is still limited. Therefore, we aimed to develop radiofluorinated molecule resembling structure therapeutic PSMA-617. <b>Methods:</b> The nonradioactive reference compound PSMA-1007 and precursor were produced by solid-phase...
Here we aim to provide updated guidance and standards for the indication, acquisition, interpretation of PSMA PET/CT prostate cancer imaging. Procedures characteristics are reported a variety available small radioligands. Different scenarios clinical use PSMA-ligand discussed. This document provides clinicians technicians with best evidence, support implementation imaging in research routine practice.
Since prostate-specific membrane antigen (PSMA) is up-regulated in nearly all stages of prostate cancer (PCa), PSMA can be considered as a viable diagnostic biomarker and treatment target PCa. This project focused on the development evaluation series compounds directed against PSMA. The modifications to linker are designed improve binding potential pharmacokinetics for theranostic application. In addition, results help further elucidate structure-activity relationships (SAR) resulting...
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified PSMA PET imaging. Promising results PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations targeting molecules radiolabels. Definitive evidence safety efficacy [177Lu]Lu-PSMA-617 combination standard-of-care has demonstrated metastatic...
Matrix metalloproteinases (MMPs) are enzymes involved in the proteolytic degradation of extracellular matrix. They play an important role several disease processes, such as inflammation, cancer, and atherosclerosis.In this study, we have used broad-spectrum MMP inhibitor CGS 27023A to develop radioligand [123I]I-HO-CGS for vivo imaging activity. Using radioligand, were able specifically image activity by scintigraphy MMP-rich vascular lesions that after carotid artery ligation...
The introduction of <sup>18</sup>F-labeled prostate-specific membrane antigen (PSMA)–targeted PET/CT tracers, first <sup>18</sup>F-DCFPyL (2-(3-{1-carboxy-5-[(6-<sup>18</sup>F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) and more recently <sup>18</sup>F-PSMA-1007...